Tildrakizumab Found Effective, Safe in Elderly Patients With Psoriasis
A multicenter study finds no difference in outcomes between frail and nonfrail elderly patients treated with tildrakizumab over 2 years.
Previous Post
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
Next Post
Patient Satisfaction Higher With Certain Breast Reconstruction Techniques
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago